RBC Capital Raises Price Target for Addus HomeCare to $134, Analyst Maintains "Outperform" Rating
ByAinvest
Friday, Aug 22, 2025 9:20 pm ET1min read
ADUS--
Barclays has raised its target to $109, while TD Cowen has increased its target to $139. The average analyst target price for ADUS stands at $140.82, indicating a potential 23.33% upside from the current price of $114.18 [1].
Addus HomeCare Corporation provides a range of home care services, including personal care, hospice care, and home health services. These segments cater to various patient needs, from non-medical assistance with activities of daily living to palliative care and skilled nursing services [2].
The latest price target adjustment by RBC Capital Markets underscores the analyst community's optimism regarding ADUS's growth potential. As the demand for home care services continues to rise, driven by an aging population and increased healthcare needs, companies like Addus HomeCare are well-positioned to benefit.
Investors should closely monitor ADUS's financial performance and any updates from the company or analysts to gauge the stock's future prospects. Given the current analyst consensus and price targets, ADUS presents an intriguing opportunity for investors seeking exposure to the home care sector.
References:
[1] https://www.marketscreener.com/news/addus-homecare-insider-sold-shares-worth-2-873-851-according-to-a-recent-sec-filing-ce7c50dad88ff52c
[2] https://www.marketbeat.com/ratings/by-issuer/royal-bank-of-canada-stock-recommendations/
RBC Capital has raised its price target for Addus HomeCare (ADUS) to $134, maintaining its "Outperform" rating. The stock has seen several analyst actions in recent months, with Barclays raising its target to $109 and TD Cowen increasing its target to $139. The average analyst target price is $140.82, indicating a 23.33% upside from the current price of $114.18.
RBC Capital Markets has recently updated its price target for Addus HomeCare Corporation (ADUS), raising it to $134. The investment bank maintains its "Outperform" rating for the stock, reflecting a positive outlook on the company's financial prospects. This move comes amidst a flurry of analyst actions in recent months, with Barclays and TD Cowen also adjusting their price targets for ADUS.Barclays has raised its target to $109, while TD Cowen has increased its target to $139. The average analyst target price for ADUS stands at $140.82, indicating a potential 23.33% upside from the current price of $114.18 [1].
Addus HomeCare Corporation provides a range of home care services, including personal care, hospice care, and home health services. These segments cater to various patient needs, from non-medical assistance with activities of daily living to palliative care and skilled nursing services [2].
The latest price target adjustment by RBC Capital Markets underscores the analyst community's optimism regarding ADUS's growth potential. As the demand for home care services continues to rise, driven by an aging population and increased healthcare needs, companies like Addus HomeCare are well-positioned to benefit.
Investors should closely monitor ADUS's financial performance and any updates from the company or analysts to gauge the stock's future prospects. Given the current analyst consensus and price targets, ADUS presents an intriguing opportunity for investors seeking exposure to the home care sector.
References:
[1] https://www.marketscreener.com/news/addus-homecare-insider-sold-shares-worth-2-873-851-according-to-a-recent-sec-filing-ce7c50dad88ff52c
[2] https://www.marketbeat.com/ratings/by-issuer/royal-bank-of-canada-stock-recommendations/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet